A detailed history of Ubs Oconnor LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Ubs Oconnor LLC holds 721,768 shares of IFRX stock, worth $1.15 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
721,768
Holding current value
$1.15 Million
% of portfolio
0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.74 $400,443 - $590,484
339,359 Added 88.74%
721,768 $1.26 Million
Q1 2024

May 15, 2024

BUY
$1.47 - $2.03 $265,377 - $366,473
180,529 Added 89.42%
382,409 $588,000
Q4 2023

Feb 14, 2024

SELL
$1.25 - $2.75 $235,150 - $517,330
-188,120 Reduced 48.24%
201,880 $329,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $226,100 - $368,050
85,000 Added 27.87%
390,000 $1.16 Million
Q2 2023

Aug 14, 2023

BUY
$2.05 - $6.1 $625,250 - $1.86 Million
305,000 New
305,000 $1.36 Billion

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $70.7M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.